The main goals of chronic obstructive pulmonary disease (COPD) management include treatment of symptoms and prevention of exacerbations. Current guidelines recommend use of one or more long-acting ...

Chronic obstructive pulmonary disease (COPD) management should take into account patients’ comorbidities, according to a poster presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting.

Chronic obstructive pulmonary disease (COPD) is a long-term lung disease affecting at least 15 million American adults. It’s also the fourth leading cause of disease-attributed death. This makes ...

telemedicine Researchers examined the risks for pneumonia and exacerbation of COPD after PPI treatment for GERD. The risk for symptom exacerbation reduced after PPI treatment for patients with GERD ...

—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...

Almost 16 million adults have COPD in the United States and about 3 in 4 people with this condition have at least one flare (exacerbation) a year, cites a review. But you don’t have to sit and wait ...

Please provide your email address to receive an email when new articles are posted on . Common genetic variants do not appear to play an important role in predicting acute exacerbations of COPD or ...

The results of this systematic review suggest that there is a modest relative risk reduction in COPD exacerbations with the use of ICS. In the sensitivity analysis, the beneficial effect was noted ...

NEW ORLEANS, Oct. 14, 2019 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) exacerbations surge during the coldest months of the year—January, February and March—creating a spike in COPD ...

Inhaled maintenance therapy is underused among hospitalized patients with COPD in China, even in those with frequent prior hospitalizations.

This cost analysis using data from the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial found that fluticasone furoate/vilanterol reduced the rates and costs of combined chronic ...